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The MYC proto-oncogene is a transcription factor
implicated in a broad range of cancers. MYC is regu-
lated by several post-translational modifications
including SUMOylation, but the functional impact of
this post-translational modification is still unclear.
Here, we report that the SUMO E3 ligase PIAS1
SUMOylates MYC. We demonstrate that PIAS1 pro-
motes, in a SUMOylation-dependent manner, MYC
phosphorylation at serine 62 and dephosphorylation
at threonine 58. These events reduce the MYC turn-
over, leading to increased transcriptional activity.
Furthermore, we find that MYC is SUMOylated in pri-
mary B cell lymphomas and that PIAS1 is required for
the viability of MYC-dependent B cell lymphoma
cells as well as several cancer cell lines of epithelial
origin. Finally,Pias1-null mice display endothelial de-
fects reminiscent of Myc-null mice. Taken together,
these results indicate that PIAS1 is a positive regu-
lator of MYC.INTRODUCTION
The MYC proto-oncogene encodes a basic helix-loop-helix
leucine-zipper (bHLH-LZ) transcription factor causally impli-
cated in a wide range of human cancers (Dang, 2012). Genetic
evidence indicates that MYC is required for the maintenance of
B cell lymphomas (Jain et al., 2002; Karlsson et al., 2003): this
finding suggests that inhibition of MYC or of MYC-dependent
oncogenic networks would be of therapeutic value. Because
MYC is currently undruggable, the discovery of cellular networks
that may present an Achilles’ heel for MYC-driven tumors is a
high priority in cancer research.
MYC turnover is tightly regulated in resting cells, mostly
through phosphorylation of serine 62 (S62), which promotes
MYC activation and also primes the phosphorylation of threonine2266 Cell Reports 15, 2266–2278, June 7, 2016 ª 2016 The Author(s
This is an open access article under the CC BY-NC-ND license (http://58 (T58) with consequent recruitment of the ubiquitination ma-
chinery responsible for MYC degradation (Amati, 2004; Sears
et al., 2000; Welcker et al., 2004; Yada et al., 2004). As a result,
MYC is maintained at low levels in non-transformed cells. In
contrast, in cancer cells MYC is often upregulated by chromo-
somal rearrangements (for instance, by t(8;14) in Burkitt’s lym-
phoma), gene amplification, or by mutation of T58 (Dalla-Favera
et al., 1982; Hemann et al., 2005).
Here, we report that a SUMO E3 ligase, protein inhibitor of
activated STAT1 (PIAS1), physically interacts withMYC, promot-
ing its stabilization and oncogenic activity in MYC-driven B cell
lymphomas.
SUMOylation consists of the reversible covalent conjugation of
the small ubiquitin-like modifiers (SUMO1, SUMO2, or SUMO3)
to acceptor lysines on target substrates with an enzymatic
cascade that involves E1, E2, (SAE1/2 and UBC9, respectively),
and a limited number of SUMO E3 ligases. Typically, only a small
fraction of a given protein is SUMOylated (Flotho and Melchior,
2013).
SUMOylation regulates several fundamental cellular pro-
cesses, and it has also been implicated in the regulation of
several oncogenes and tumor suppressors. However, cancer-
associated mutations activating a SUMO E3 ligase tend not to
be seen (Bettermann et al., 2012). Nevertheless, the SAE1/2
SUMO E1 ligase is essential for the viability of MYC-dependent
breast cancer cell lines (Kessler et al., 2012). Targeting the
SUMOylation machinery leads to detrimental effects in B cell
lymphoma cells as well (Hoellein et al., 2014). These observa-
tions suggest that components of the cellular machinery that
SUMOylates MYC represents a potential therapeutic target.
In this regard, it is noteworthy that MYC and N-MYC are
SUMOylated (Kalkat et al., 2014; Sabo` et al., 2014a). Very
recently, it was also reported that PIAS1 is a MYC SUMO E3
ligase that promotes the degradation of MYC by the proteasome
(Gonza´lez-Prieto et al., 2015). However, this latter studywas per-
formed in the U2OS cell line in vitro, raising the concern that
these findings might not be generalizable to other cellular con-
texts. As a consequence, very little is known regarding the bio-
logical significance of the interaction between PIAS1 and MYC,).
creativecommons.org/licenses/by-nc-nd/4.0/).
the functional consequences of MYC SUMOylation, or whether
PIAS1 plays a direct functional role in tumorigenesis.
PIAS1 has been implicated in the regulation of several onco-
genes and tumor suppressors (Galanty et al., 2009; Li et al.,
2013; Morris et al., 2009; Rabellino et al., 2012). In addition,
PIAS1 is overexpressed in prostate and lung cancers (Hoefer
et al., 2012; Rabellino et al., 2012). These findings suggest that
PIAS1 is involved in the regulation of oncogenic networks.
In this study, we characterized the interaction between PIAS1
and MYC, reaching the conclusion that PIAS1 is a positive regu-
lator of MYC, required to maintain MYC oncogenic activity.
RESULTS
PIAS1 and MYC Collaborate in Transformation Assays
and Physically Interact
We found that PIAS1 stimulates the growth in clonogenic assays
of immortalized human bronchoalveolar cells (HBEC13) and of
NIH 3T3 cells. These cell lines are commonly used in transforma-
tion assays (Figures 1A and S1A–S1C) (Copeland et al., 1979;
Ramirez et al., 2004). To begin testing whether this interaction
is of significance in human cancer, we studied PIAS1 and MYC
by immunohistochemistry (IHC) in diffuse large B cell lymphoma
(DLBCL) (Ott et al., 2013), a cancer where MYC is deregulated.
We examined two independent cohorts of patients, for a total
of 106 cases, using a scoring system that takes into account
the number of positive cells present in the sample. We found
that a significant percentage of DLBCLs are positive for both
PIAS1 and MYC (Figures 1B, 1C, and S1D). In contrast, PIAS1
and MYC are negative in healthy lymphoid tissues, with the
exception of few positive scattered cells (Figure S1E). Lym-
phomas originated from iMycEm-I mice (iMyc hereafter) also
stain-positive for PIAS1 and MYC (Figure S1F). This finding is
of relevance because these mice express histidine-tagged
MYC (6His-MYC) under the control of the immunoglobulin
heavy chain enhancer, which recapitulates the genetic alteration
and biological features of t(8;14) of Burkitt’s lymphoma (Park
et al., 2005). Taken together, these data suggest that PIAS1
and MYC collaborate in lymphomagenesis.
We found that PIAS1 and MYC readily co-immunoprecipitate
(coIP) either when ectopically expressed in HEK293T cells or
when endogenously expressed in human and murine MYC-
dependent B cell lymphoma cells (i.e., P493-6, iMycEm-I, and
815Luc B cell lymphoma cell lines, which originated from
iMycEm-I mice and therefore express 6His-MYC), breast cancer,
and lung cancer cell lines (Figures 1D, 1E, and S1G–S1I).
Next, we cultured primary murine B cells to characterize the
interaction between PIAS1 and MYC. We found that PIAS1 and
MYC are barely expressed in resting B cells; however, both
PIAS1 andMYC are readily detectable in B cells after stimulation
with lipopolysaccharide (LPS) or with LPS and interleukin-4 (IL4)
(Hoellein et al., 2014; Sakurai et al., 2011). PIAS1 and MYC
weakly coIP in resting B cells but readily coIP in LPS- and
LPS/IL4-treated B cells. However, the addition of IL4 to LPS
decreased the interaction between PIAS1 and MYC. Further-
more, we noticed that MYC immunoprecipitated from LPS-stim-
ulated B cells runs as doublet in western blot (WB). These obser-
vations indicate that PIAS1 and MYC interact also in primary,non-transformed B cells. It is also likely that IL4 regulates cellular
networks that decrease the interaction between PIAS1 andMYC
(Figures 1F and S1J).
We also found that PIAS1 and MYC also readily coIP when
produced in bacteria and by in vitro transcription/translation re-
action (Figures 1G, S1K, and S1L), indicating that the two pro-
teins interact directly. Finally, both endogenous and exoge-
nously expressed PIAS1 and MYC colocalize in the cell
nucleus (Figures S1M and S1N).
We performed coIP experiments to determine which protein
domains are required for the interaction between MYC and
PIAS1. With a panel of MYC deletion mutants (Table S1), we
determined that deletion of the N-terminal region together with
the MBI domain of MYC (amino acids 1–63, MYC DN/DMBI)
severely impairs the interaction with PIAS1 (Figure 1H). Next,
we found that the deletion of the RING domain (PIAS1 DRING),
which mediates protein-protein interactions and is also respon-
sible for its SUMO E3 ligase activity (Liu et al., 2014b; Palvimo,
2007), severely impairs the ability of PIAS1 to interact with
MYC (Figure 1I). Notably, deletion of the RING domain does
not interfere with the nuclear localization of PIAS1 (Figure S1O).
Even though the deletion of the RING domain decreases by
30% the steady state of PIAS1 protein (Figure 1I, input), which
could hamper the interpretation of coIP experiments, we
conclude that PIAS1 DRING is severely impaired in its ability to
interact with MYC. Taken together, these data indicate that
PIAS1 and MYC functionally and physically interact.
PIAS1 Upregulates MYC, Preventing Its Degradation
Weobserved that ectopic expression of PIAS1 upregulatesMYC
(Figures 1H, 1I, S1G, S1H, and S2A). The observation that
ectopic expression of PIAS1 does not affect MYC mRNA abun-
dance indicates that MYC is not upregulated transcriptionally
(Figure S2B). Because MYC protein is mainly regulated by
post-translational modifications (Amati, 2004), we determined
whether PIAS1 affects the half-life of MYC. We found that
PIAS1 extends the half-life of MYC from 1 hr to 4 hr both with
pulse- and chase-labeling experiments with 35S methionine
and by incubation of HEK293T cells with the inhibitor of protein
translation cycloheximide (Figures 2A, 2B, S2C, and S2D).
PIAS1 DRING, that cannot bind to MYC and that is also SUMO
E3 ligase dead, fails to upregulate or stabilize MYC (Figures 2C
and S2E). Conversely, silencing of PIAS1 in HeLa cells exoge-
nously expressing MYC, leads to increased turnover of MYC
(Figure 2D). Finally, PIAS1 knockdown in iMycEm-I B cell lym-
phoma cells significantly downregulates MYC protein (Fig-
ure S2F). Taken together, these results indicate that the ability
of PIAS1 to stabilize MYC depends on the capacity of PIAS1 to
interact with it.
To further examine the role of PIAS1 in the regulation of MYC
stability, we investigated whether PIAS1 affects MYC ubiquiti-
nation. PIAS1 did not significantly alter MYC ubiquitination
in HEK293T cells (Figure S2G). Ectopic expression of PIAS1
and SUMO2 modestly reduced MYC ubiquitination without
affecting MYC upregulation (Figure S2H). In addition, transfec-
tion of ubiquitin did not affect the ability of PIAS1 to increase
MYC protein (Figures S2G and S2H). These findings occur
even though the SUMO-dependent ubiquitin E3 ligase RNF4,Cell Reports 15, 2266–2278, June 7, 2016 2267
Figure 1. PIAS1 Physically and Functionally Interacts with MYC
(A) Clonogenic assay on soft agar of HBEC13 cells transduced as indicated.
(B) The histogram shows the percentage of B cell lymphomas that are either positive or negative for PIAS1 and MYC in a tumor tissue array of 62 samples.
(C) Representative IHC-positive staining of a diffuse large B cell lymphoma (DLBCL) specimen stained as indicated. Scale bars, 500 mm and 100 mm.
(D) The cell lysate of P493-6 B cells was analyzed by IP followed by WB.
(E) iMycEm-I B cell lymphoma cells were analyzed by histidine-pull down followed by WB.
(F) Naive B cells isolated from spleens were treated for 4 hr with LPS or LPS and IL4 and analyzed by IP and WB.
(G) In vitro binding assay of bacterially produced PIAS1 and MYC. Proteins were coIP as indicated and analyzed by WB.
(H and I) HEK293T cells were transfected as indicated and analyzed by coIP followed by WB.
See also Figure S1 and Table S1.which has been implicated in the degradation of MYC (Gonza´-
lez-Prieto et al., 2015), is readily detectable in HEK293T cells
(Figure S2I). Finally, overexpression of the ubiquitin E3 ligase
FBW7, which is the main MYC ubiquitin E3 ligase involved in
MYC ubiquitination (Welcker et al., 2004; Yada et al., 2004),
did not override the ability of PIAS1 to upregulate MYC (Fig-
ure S2J). We conclude that PIAS1 does not significantly affect
MYC ubiquitination.
PIAS1 SUMOylates MYC in B Cell Lymphoma In Vivo
We determined that MYC is SUMOylated in vivo in B cell lym-
phomas and in B cell lymphoma cell lines (i.e., iMycEm-I,815Luc
and MMS.1-R lymphoma cells) derived from iMyc mice with an
assay that specifically purifies 6His-MYC in denaturing condi-
tions that exclude non-covalently bound proteins (Figures 3A,
3B, and S3A) (Boylan et al., 2007; Han et al., 2005; Lallemand-2268 Cell Reports 15, 2266–2278, June 7, 2016Breitenbach et al., 2008; Rabellino et al., 2012; Tatham et al.,
2009). Importantly, we did not isolate SUMOylated bands in
B cells of non-transgenic littermates, demonstrating that the
detection of SUMOylated MYC is specific (Figure 3C).
Next, we found that silencing of PIAS1 in iMycEm-I lymphoma
cells reduces the SUMOylation of MYC to a degree that parallels
the efficiency of the knockdown (Figures 3D and S3B). This
finding supports the notion that the SUMOylation of MYC is
PIAS1-dependent.
We found that PIAS1 readily SUMOylates MYC in an in vitro
SUMOylation assay that utilizes recombinant proteins (Fig-
ure 3E). Furthermore, with affinity purification assays of 6His-
MYC in denaturing conditions, we found that PIAS1 readily pro-
motes the SUMOylation of MYC in transfected cells (Figure 3F).
Importantly, this affinity purification procedure is specific as
demonstrated by the absence of SUMOylated proteins in lysates
Figure 2. PIAS1 Prevents MYC Degradation
(A) 35S methionine pulse and chase experiment in
HEK293T cells transfected as indicated. Incorpo-
ration of 35S methionine was measured in immu-
noprecipitated MYC at the indicated time points.
(B and C) HEK293T cells were transfected and
treated with cycloheximide (CHX) as indicated and
analyzed by WB. The intensity of the bands was
quantified by densitometry: the ratio between
MYC and tubulin is presented at the bottom of the
panel.
(D) HeLa cells stably transduced with the indicated
retroviral vectors and shRNAs were treated with
cycloheximide (CHX) and analyzed by WB.
See also Figure S2.transfected with EGFP-SUMO1 and PIAS1 (Figure S3C). Simi-
larly, DRING PIAS1, which is defective in its interaction with
MYC, does not promote MYC SUMOylation (Figure S3D).
To identify the residues of MYC that PIAS1 SUMOylates,
we systematically introduced lysine (K) to arginine (R) substitu-
tions in the sequence of 6His-MYC. We determined that ablation
of MYC lysine 51 and 52 (6His-MYC K51/52R) strikingly de-
creases 6His-MYC SUMOylation (Figure 3G, central panel; Fig-
ure S3E shows a longer exposure of the same western blot
shown in Figure 3G). Additional ablation of the lysines 143,
148, 206, 328, 389, 422, 428, and 430 (MYCK51/52RCTD, there-
after) further decreases the SUMOylation of 6His-MYC (Figures
3G, right panel, and S3E). Notably, MYC K residues 52, 326,
430, and 389 are predicted high probability and low probability
SUMOylation sites, respectively, and were recently identified
by mass spectrometry or site directed mutagenesis also by
others (Tables S2A andS2B) (Gonza´lez-Prieto et al., 2015; Kalkat
et al., 2014; Sabo` et al., 2014a).Cell RTaken together, these experiments
indicate that lysines 51 and 52 are
the major MYC SUMOylated sites and
they are required for further MYC
SUMOylation events.
PIAS1 Increases the Half-Life of
MYC in a SUMOylation-Dependent
Manner
Next, we determined whether the
ability of PIAS1 to stabilize MYC is
SUMOylation-dependent. We noticed
that PIAS1 W372A, which lacks SUMO
E3 ligase activity, but retains the ability
to bind to MYC (Figure 4A), neither upre-
gulates nor stabilizes MYC (Figure 4B;
Figure S4A shows western blots and his-
togram summarizing the results of three
independent experiments) (Liu et al.,
2014a). Furthermore, PIAS1 affects only
partially the half-life of the SUMO-
deficient MYC K51/52R mutant (Fig-
ure 4C; Figure S4B shows western blots
and histogram summarizing the resultsof three independent experiments). Taken together, these
results indicate that the ability of PIAS1 to stabilize MYC
depends on the capacity of PIAS1 to interact with and to
SUMOylate MYC.
PIAS1 Enhances the Transcriptional Activity of MYC
We assessed the functional relevance of the interaction be-
tween PIAS1 and MYC. We found that PIAS1 strikingly upregu-
lates the transcriptional activity of a synthetic promoter con-
taining an E-box. PIAS1 also collaborates with MYC in this
assay but does not affect a mutated E-box (Figures 5A and
S5A) (Hermeking et al., 2000). We also found that PIAS1 strik-
ingly upregulates the transcriptional activity of MYC but not of
the SUMO-deficient MYC K51/52R mutant (Figure 5B). Finally,
PIAS1 knockdown in HeLa cells inhibits the transcriptional ac-
tivity of MYC, but not of MYC K51/52R (Figures 5C and S5B).
Furthermore, ectopically expressed PIAS1 also remarkably
upregulates the ability of MYC, but not of MYC K51/52R, toeports 15, 2266–2278, June 7, 2016 2269
Figure 3. PIAS1 SUMOylates MYC
(A) WB of histidine-purified 6His-Myc from a lymphoma originated from an iMyc mouse.
(B) Histidine-purification followed by WB of iMycEm-I lymphoma cells.
(C) iMycEm-I lymphoma cells and B cells derived from non-transgenic littermates were analyzed by histidine purification followed by WB.
(D) WB of 6His-Myc histidine-purified from iMycEm-I lymphoma cells expressing the indicated shRNAs. Ren: shRNA against Renilla.
(E) In vitro SUMOylation reaction analyzed by WB.
(F and G) Transiently transfected HEK293T cells were analyzed by histidine-purification followed by WB. Vertical bar indicates the presence of SUMOylated
conjugates. The asterisk indicates a background band.
See also Figure S3 and Table S2.express endogenous RGS16 and BLMH (Figures 5D and
S5C), which are well-known MYC target genes (Kessler et al.,
2012). Taken together, these data indicate that PIAS1 upregu-
lates MYC transcriptional activity in a SUMOylation-dependent
manner.
In order to be transcriptionally active, MYC requires its heter-
odimerization with MAX (Grandori et al., 2000). Thus, it is note-
worthy that PIAS1 causes a degree of upregulation of MYC
that leads to increased formation of MYC/MAX heterodimers.
Notably, the MYC/MAX complexes also interact with PIAS1 (Fig-
ure 5E). PIAS1 does not promote the upregulation of MYC K51/
52R and MYC K51/52RCTD and, as expected, we found that
PIAS1 does not increase their interaction with MAX (Figure 5F,
lanes 5 and 7). PIAS1 does not affect the steady state of MAD,
which negatively regulates MYC transcriptional activity by bind-
ing to MAX (Figure S5D).
We conclude that PIAS1 promotes the formation of
MYC/MAX heterodimers increasing the transcriptional activity
of MYC.2270 Cell Reports 15, 2266–2278, June 7, 2016PIAS1 Opposes MYC Degradation by Inhibiting MYC
Phosphorylation at T58 and Stimulating
Phosphorylation of MYC S62
Our data indicate that PIAS1 upregulates MYC and positively
regulates its transcriptional activity. For these reasons, we deter-
mined whether PIAS1 modulates the phosphorylation events
that regulate the activation and/or the turnover of MYC.
Phosphorylation of MYC S62 critically regulates the activation
of MYC and also primes the phosphorylation of T58, which medi-
ates the recognition of MYC by the ubiquitin/proteasomal degra-
dation machinery (Amati, 2004; Gregory et al., 2003; Sears et al.,
2000). Prompted by our finding that PIAS1 increases the half-life
of MYC, we tested whether PIAS1 regulates the phosphorylation
ofMYCT58 and S62with phospho-specific antibodies.We found
that ectopicexpressionofPIAS1causes theupregulationofphos-
phorylated MYC with an antibody that recognizes MYC singly or
doubly phosphorylated at T58 and S62 (Figure S6A). Because
phosphorylation of these sites causes divergent functional out-
comes (phosphorylation of T58 causes MYC degradation, while
Figure 4. SUMOylation Regulates MYC Half-Life
(A) Transiently transfected HEK293T cells were analyzed by IP followed by WB.
(B and C) HEK293T cells transfected as indicated were treated with cycloheximide (CHX) and analyzed by WB. The intensity of the bands was quantified by
densitometry and the ratio between MYC and tubulin is presented at the bottom of the panel.
See also Figure S4.phosphorylation of S62 its activation), we determined whether
preferential changes in phosphorylation occur at these residues.
To this end, we used MYC mutants carrying threonine and/or
serine to alanine substitutions of MYC T58 or S62. This strategy
also allows assessing of the specificity of phosphorylation
changes detected by phospho-specific antibodies. We found
that once upregulated by PIAS1, MYC is preferentially phosphor-
ylated MYC S62 (Figure 6A, upper panel; Figures S6B–S6D show
additional representativewestern blots and histograms summari-
zing the results of three independent experiments; note that upre-
gulatedMYC andMYC T58A are phosphorylated on S62). On the
contrary,we found thatPIAS1downregulates thephosphorylation
ofMYCT58 (Figure 6A, lower panel; FiguresS6B–S6Dshowaddi-
tional western blots and histograms summarizing the results
of three independent experiments; note that despite a striking
increase in MYC protein levels the phosphorylation of T58 is
dramatically decreased). Furthermore, we determined that abla-
tionof theSUMOE3 ligaseactivity ofPIAS1ablates thephosphor-
ylation of MYC S62 (Figure 6B). Phosphorylation of MYC S62 is
associated with stabilization/upregulation of MYC and increased
MYC transcriptional activity. Thus, these observations are
consistent with our finding that PIAS1 increases the transcrip-
tional activity of MYC (Figures 5A–5D).
Next, we determined that PIAS1 does not upregulate the
phosphorylation of S62 of the SUMO-deficient MYC K51/52Rand K51/52RCTD mutants (Figure 6C, compare lanes 4 and 5
and lanes 6 and 7 to lanes 2 and 3). Furthermore, we determined
that PIAS1 SUMOylates MYC, MYC T58A, MYC S62A, and MYC
T58/S62A similarly (Figure 6D). This result suggests that MYC
SUMOylation does not require a pre-existing phosphorylation
of MYC S62 and/or T58. Instead, these data support the conclu-
sion that PIAS1 upregulates MYC by promoting the phosphory-
lation of MYC at S62 but not at T58.
JNK1andGSK3bare amongseveral protein kinases that phos-
phorylate MYC S62 and T58, respectively (Amati, 2004; Gregory
et al., 2003; Noguchi et al., 1999). For this reason, we tested
whether PIAS1 affects the interaction of MYC with JNK1 or
GSK3b. Indeed, ectopic expression of PIAS1 promotes the inter-
action of MYCwith JNK1 (Figure 6E). Importantly, MYC K51/52R
does not interact with JNK1 in coIP (Figure S6E). On the contrary,
PIAS1 decreases the interaction of GSK3b and MYC (Figure 6F).
This findingwas also consistentwith our observation that overex-
pression of the ubiquitin E3 ligase FBW7, which is the main MYC
ubiquitin E3 ligase that recognizes P-58 and P-62 to trigger ubiq-
uitination (Welcker et al., 2004; Yada et al., 2004), did not override
the ability of PIAS1 to upregulateMYC (Figure S2J). These results
were also consistent with our findings that PIAS1 does not in-
crease MYC ubiquitination (Figures S2G and S2H).
These results support a model whereby PIAS1, likely via
SUMOylation, reduces the turnover of MYC by recruiting JNK1,Cell Reports 15, 2266–2278, June 7, 2016 2271
Figure 5. PIAS1 Upregulates MYC Transcriptional Activity
(A and B) Transactivation assay in transfected HEK293T cells; p-BV-Luc expresses luciferase under the control of a MYC-responsive E-Box. WT, wild-type; Mut,
mutant.
(C) Transactivation assay with p-BV-Luc in HeLa cells stably expressing the indicated retroviruses and shRNAs targeting PIAS1.
(D) HEK293T cells were transiently transfected as indicated. Endogenous expression of the MYC target gene RGS16 was detected by qRT-PCR.
(E and F) CoIP assay performed in HEK293T cells transfected as indicated.
See also Figure S5.which favors the phosphorylation ofMYCS62,while opposing the
recruitment to MYC of GSK3b with consequent reduction of T58
phosphorylation (Figure 6F). Finally, using a tandem affinity purifi-2272 Cell Reports 15, 2266–2278, June 7, 2016cation that uses an anti-SUMO1 or anti-SUMO2 antibodies
that recognize native SUMOylated proteins (step 1) followed by
nickel-beads purification (step 2) (Figure S6F) (Becker et al.,
Figure 6. PIAS1 Promotes the Phosphorylation of MYC Serine 62
(A–C)WBanalysis of HEK293T cells transfected as indicated. (C) The intensity of the bandswas quantified by densitometry and the ratio between P-S62 andMYC
is shown at the bottom of the panel.
(D) Histidine purification of transiently transfected HEK293T cells followed by WB analysis.
(E) CoIP of HEK293T cells transiently transfected as indicated.
(F) Proposed mechanism by which PIAS1 stabilizes MYC: PIAS1 SUMOylates MYC recruiting the kinase JNK1 (that phosphorylates S62) while suppressing the
interaction with GSK3b (that phosphorylates T58).
See also Figure S6.2013),wedetermined that endogenous6His-MYC in iMycEm-I lym-
phoma cells is also SUMOylated by SUMO2 (Figure S6G).
PIAS1 Promotes the Ability of MYC to Stimulate Cell
Proliferation and Survival in MYC-Driven B Cell
Lymphoma
To determine whether the interaction of PIAS1 with MYC is of
biological relevance, we tested whether PIAS1 affects the ability
of MYC to promote cell proliferation. Transfection of PIAS1 with
MYC in HEK293T cells significantly stimulates the phosphoryla-
tion of RNA polymerase II (RNAPolII), a well-known readout of
MYC activity (Figure S7A) (Gomez-Roman et al., 2003). As ex-
pected, reintroduction ofMYC restored the proliferation capacity
of HO15.19 Rat-1 fibroblasts, in whichMyc had been inactivated
by homologous recombination (Mateyak et al., 1997). However,
reintroduction of MYC K51/52R or MYC K51/52RCTD did not
restore the proliferation of HO15.19 cells (Figures 7A and S7B).
Increased expression of MYC or MYC K51/52R in HO15.19 did
not further increase the level of cell proliferation. The fact that
wild-type MYC does not increase cell proliferation is consistent
with the fact that a threshold of MYC is generally required for
optimal cell proliferation (Figure S7C). These data support the
conclusion that PIAS1 regulates the biological activity of MYC
in a SUMOylation-dependent manner.To further assess the biological function of PIAS1, we took
advantage of P493-6 and iMycEm-I lymphoma cells. In these
cell lines, PIAS1 knockdown downregulates MYC, phospho-
RB, and RNAPolII (Figure S7D), with concomitant striking inhibi-
tion of cell proliferation (Figures 7B, 7C, and S7E). Silencing
PIAS1 causes striking inhibition of cell proliferation also in human
B cell lymphoma cell lines SUDHL-4 and LY-1, which harbor
MYC amplification (Figure S7F). Importantly, an RNAi-resistant
PIAS1 cDNA rescued the effect of PIAS1 silencing (Figure S7G).
Moreover, PIAS1 silencing induces the apoptotic marker
cleaved caspase-7 in P493-6 cells (Figure 7D). Finally, we deter-
mined whether PIAS1 is required for the viability of a different
MYC-dependent cellular model. We utilized MYC-dependent
MDA-MB-231 and MYC-independent MCF7 breast cancer cells
(Kessler et al., 2012). Silencing of PIAS1 did not affect the prolif-
eration of MYC-independent MCF7 cells, while it severely
decreased the proliferation of MYC-dependent MDA-MB-231
cells (Figures 7E, 7F, and S7H).
PIAS1 and MYC Cooperate In Vivo
To gain insight into the significance of the interaction between
PIAS1 and MYC in vivo, we performed xenograft experiments
using iMycEm-I lymphoma cells. In this setting, silencing of
Pias1 resulted in a remarkable suppression of tumor formationCell Reports 15, 2266–2278, June 7, 2016 2273
Figure 7. PIAS1 Promotes the Tumorigenic Activity of MYC
(A) Myc-null HO15.19 Rat-1 fibroblasts were stably transduced with retroviruses expressing the indicated genes. The graph shows their proliferation capacity
(note that the black and blue lines are superimposed). Representative color-coded crystal violet stained culture wells are shown in the bottom panel.
(B and C) Proliferation assay of P493-6 human lymphoma B cells and murine iMycEm-I lymphoma B cells stably expressing the indicated shRNAs.
(D) WB analysis of P493-6 cells stably expressing the indicated shRNAs.
(E and F) Proliferation assays performed on MCF7 (MYC-independent) and MDA-MB-231 (MYC-dependent) breast cancer cell lines stably expressing the
indicated shRNAs.
(G) Tumor volume of iMycEm-I lymphoma cells transduced as indicated and implanted in nudemice. Xenograft volume wasmeasured over a 48-day period. Mean
and SEM, n = 6.
(H) Proposed biological function of PIAS1 in B cells. At physiological levels, PIAS1 promotes the expansion and differentiation of B cells through activation of
MYC; in conditions of PIAS1 upregulation or deregulation of MYC (as it occurs in the t(8;14)), PIAS1 promotes supra-physiological activation ofMYC contributing
to lymphomagenesis.
See also Figures S7 and S8.compared to control xenografts. At the study endpoint, PIAS1
was still suppressed (Figures 7G and S7I). These results indicate
that Pias1 is required for the growth of MYC-driven lymphomas
in vivo.
To further assess whether Pias1 and Myc interact in vivo, we
analyzed Pias1-null embryos (Figures S8A–S8C), which were
previously reported to be born at a reduced Mendelian ratio
and also to experience perinatal lethality (Liu et al., 2004). We
found that yolk sacs of Pias1-null mice at E13.5 are developmen-
tally delayed, hypoplastic and devoid of their microvillar pattern
(Figure S8D). These features are characteristic of yolk sacs of
Myc-null mice (Baudino et al., 2002; He et al., 2008). Notably,
MYC IHC staining is significantly reduced in the yolk sacs of2274 Cell Reports 15, 2266–2278, June 7, 2016Pias1-null mice (Figures S8E and S8F). Taken together, these
findings support the notion that Pias1 is a positive regulator of
Myc in vivo.
DISCUSSION
We report a function for the SUMO E3 ligase PIAS1, finding that
PIAS1 not only directly upregulates the MYC proto-oncogene
through a mechanism that promotes stabilization, but it also in-
creases the capacity of MYC to drive the growth of B cell lym-
phoma cells both in vitro and in vivo.
Although MYC has been intensely studied, SUMOylation has
only recently been implicated in its regulation (Kessler et al.,
2012). In addition, very recent studies report that MYC un-
dergoes SUMOylation, and PIAS1 is implicated in this process
(Gonza´lez-Prieto et al., 2015; Kalkat et al., 2014; Sabo` et al.,
2014a). However, these studies were limited to ectopically ex-
pressed proteins in highly transformed cell lines, and no evi-
dence was provided that the interaction between PIAS1 and
MYC has functional significance in a disease-relevant experi-
mental system. Thus, it has remained unclear whether PIAS1
has a role in MYC-dependent tumorigenesis and/or whether its
interaction with MYC has a biological significance. Finally, very
little is still known regarding the mechanistic underpinning and
biological significance of the interaction of the SUMOylation ma-
chinery with MYC.
Our work reveals an additional layer of regulation of the stabil-
ity of MYC in addition to the well-established ubiquitin-depen-
dent mechanisms (Amati, 2004). Our data indicate that PIAS1
stabilizes MYC through physical interaction. The observation
that mutations that abrogate the PIAS1 SUMO E3 ligase activity
impair the ability to stabilize MYC suggests that the stabilization
of MYC is SUMOylation-dependent. The observation that abla-
tion of MYC K51 and K52 decreases the half-life (and the
steady-state) of MYC lends further support to the interpretation
that direct SUMOylation extends MYC half-life. In addition, our
data suggest that PIAS1 promotes the preferential phosphoryla-
tion of MYC S62, a modification that is known to activate the
transcriptional activity of MYC. Our data also suggest that
PIAS1, by SUMOylating MYC, provides a docking surface for
JNK1, which is a known MYC S62 protein kinase. We reason
that it is likely that other kinases may utilize a similar mechanism
to phosphorylate MYC S62. On the contrary, MYC SUMOylation
prevents the phosphorylation of T58, which is involved in MYC
downregulation. This observation is consistent with the finding
that PIAS1 reduces the interaction of MYC with GSK3b, a T58
protein kinase. Moreover, this observation is also consistent
with the report that PIAS1 SUMOylates AKT, a well-known
downregulator of GSK3 (Li et al., 2013). These observations sug-
gest that PIAS1 regulates, in a coordinated manner, multiple
cellular networks that ultimately contribute to the upregulation
of MYC.
The level of upregulation of MYC caused by PIAS1 is of func-
tional significance because it leads to increased interaction of
MYC with MAX. Consistently, PIAS1 increases transcriptional
output at promoters containing E-box consensus sites and the
transcription of endogenous MYC target genes.
Our site-directed mutagenesis experiments indicate that K51
and K52 are the major MYC SUMOylation acceptor sites and
that their SUMOylation is important for the stabilization of
MYC. Their functional significance is highlighted by the fact
that their ablation significantly impairs the ability of MYC to pro-
mote cell proliferation inMyc-null Rat-1 cells. K51 and K52 are in
close proximity with T58 and S62, which play a critical role in the
regulation of MYC: this observation adds to the notion that the N
terminus of MYC is a ‘‘hot spot’’ for its regulatory framework.
Notably, others also identified K52, K148, K326, K389, and
K430, confirming the validity of our approach (Gonza´lez-Prieto
et al., 2015; Kalkat et al., 2014; Sabo` et al., 2014a).
The function, if any, of the SUMO acceptor sites in the
MYC C terminus remains to be characterized. In this regards,it has been reported that the transcriptional activity of MYC is
regulated by acetylation at lysines K143, K157, K275, K317,
K323, and K371 (Zhang et al., 2005). Some of these lysines
(i.e., 317 and 323) are also SUMOylated: it is tempting to
speculate that SUMOylation and acetylation may cross talk
to regulate several aspects of MYC biology, such as the as-
sembly of specific transcriptional complexes or the selection
of target genes (Gonza´lez-Prieto et al., 2015; Sabo` et al.,
2014a).
Our data indicate that a minority of MYC is SUMOylated.
This is a common feature of SUMOylated proteins, possibly
due to the high activity of SUMO isopeptidases in cell lysates
and/or lack of sensitivity of immunoblots. This finding is
also consistent with the absence of SUMOylated MYC from
proteome-wide identification efforts of SUMOylated substrates
(Schimmel et al., 2014; Tammsalu et al., 2014). Nevertheless,
the SUMOylation of MYC was positively identified by targeted
mass spectrometry by several groups, suggesting that the tech-
niques used for proteome-wide identification of SUMOylated
substrates may lack sensitivity or were conducted in cells that
do not express PIAS1 to a level sufficient to SUMOylate MYC
(Gonza´lez-Prieto et al., 2015; Kalkat et al., 2014). Indeed,
PIAS1 is not highly expressed in the cell generally utilized in
proteome-wide assays (i.e., HEK293T) as compared to B cell
lymphomas or PIAS1-dependent cells.
We can only speculate about the reasons of the discrepancies
between our study and the study of Gonza´lez-Prieto et al. (2015).
In transfected U2OS, MYC degradation is partially mediated
by the SUMO-targeted ubiquitin ligase RNF4 according to
Gonza´lez-Prieto et al. (2015). However, we did not detect an
appreciable upregulation of MYC ubiquitination upon PIAS1
ectopic expression even though the cells we utilized express
RNF4 and are also competent in mediating the degradation of
PML and PML-RARA upon arsenic trioxide treatment, a property
that depends on RNF4 (Lallemand-Breitenbach et al., 2008;
Rabellino et al., 2012; Tatham et al., 2008). We reason that it is
possible that this discrepancy is due to context-dependent
variables.
In this regard, we note that our data are grounded on several
cellular and in vivo systems that are germane to the biological
functions of MYC and PIAS1: the role of MYC in B cell malig-
nancies is well known and both MYC and PIAS1 are implicated
in B cell development (Delgado and Leo´n, 2010; Liu et al.,
2014a).
We observed that neither PIAS1 norMYC are highly expressed
in healthy human lymphoid tissue and in resting B cells, but both
are expressed at high levels in stimulated B cells and in a sizable
subset of primary B cell lymphomas. This observation leads us
to propose that in physiologic conditions, PIAS1 promotes the
function of MYC toward the development of mature B cells;
instead when MYC and/or PIAS1 are overexpressed and tumor
suppressors are lost, they promote lymphomagenesis (Fig-
ure 7H). It is also intriguing that PIAS1 is a putative MYC target
gene (Sabo` et al., 2014b), suggesting the possibility of a feed for-
ward loop. The observation that PIAS1 is often upregulated in
B cell lymphoma and other cancer types raises the possibility
that the enzymatic activity of PIAS1 may represent a therapeutic
target.Cell Reports 15, 2266–2278, June 7, 2016 2275
EXPERIMENTAL PROCEDURES
Cell Lines, Primary B Cell Cultures, and Chemicals
We obtained HEK293T, MCF7, MDA-MB-231, and NIH 3T3 cells from the
ATCC, iMycEm-I, and 815Luc B cell lymphoma cells from Siegfried Janz
(University of Iowa), MMs.1R B cell lymphoma cells from Bryan Van Ness
(University of Minnesota), P493-6 cells from Chi Van Dang (University of Penn-
sylvania), HO15.19 cells from John M. Sedivy (Brown University), H1437 cells
from John Minna (UT Southwestern Medical Center), and SUDHL-4 and LY-1
cells from Takahiro Maeda (Dana-Farber/Harvard Cancer Center). We ob-
tained murine primary B cells from non-transgenic littermates of iMyc mice
as described (Sakurai et al., 2011; Whitlock and Witte, 1987). Chemicals
were obtained from Sigma-Aldrich.
Plasmids and RNAi
We generated deletion mutants or point mutants by PCR-assisted mutagen-
esis or by site-directed mutagenesis. We verified by direct sequencing the
identity and integrity of all constructs. A complete list of the plasmids and small
hairpin RNA (shRNA) sequences is provided in the Supplemental Experimental
Procedures.
Proliferation and Transformation Assays
These procedures were performed as described previously (Rabellino et al.,
2012; Sakurai et al., 2011).
Immunoprecipitation, Immunoblotting, and Antibodies
These procedures were performed as described previously (Rabellino et al.,
2012). A list of the antibodies is provided in the Supplemental Experimental
Procedures.
Immunohistochemistry and Immunofluorescence
Tumor tissuemicroarray of paraffin-fixed tumor specimens were prepared and
analyzed by IHC as described previously (Rabellino et al., 2012). Two pathol-
ogists independently scored PIAS1 and MYC IHC staining. Discrepancies
were resolved by re-examination of the samples. PIAS1 and MYC staining
was scored as 0 = negative; 1 = weakly positive, less than 50%, but more
than 30% of tumor cells; 2 = moderately positive to strongly positive, greater
than 50% of tumor cells. Immunofluorescence was performed as previously
described (Rabellino et al., 2012).
In Vitro Transcription/Translation and SUMOylation In Vitro Assays
In vitro transcription/translation assays were performed following the protocol
indicated by the manufacturer (Promega). SUMOylation assays were per-
formed as described previously (Rabellino et al., 2012).
Histidine-Purification
Cells expressing His-tagged proteins were lysed with denaturing buffer (6 M
guanidinium-HCl, 100 mM NaH2PO4/Na2HPO4 [pH 8.0], 10 mM imidazole)
as described previously (Rabellino et al., 2012).
RT-PCR
RT-PCR assays were performed as previously described (Konstantinidou
et al., 2013). For a complete list the primers, please refer to the Supplemental
Experimental Procedures.
Transactivation Assays
Transcriptional assays were performed as previously described (Hermeking
et al., 2000).
Pulse and Chase Labeling Experiments
We incubated HEK293T cells 48 hr after transient transfection with 35S methi-
onine or cycloheximide (20 mg/ml) following standard protocols (Rabellino
et al., 2012).
Mouse Studies
iMyc mice (C57BL/6) mice were described previously (Park et al., 2005). Lym-
phomas that arose spontaneously were used for analysis. Xenograft experi-2276 Cell Reports 15, 2266–2278, June 7, 2016ments using iMyc cell lines (iMycEm-I) cells were done by subcutaneous inoc-
ulation of 13 106 cells into 6-week-old female NOD/SCIDmice. Tumor volume
was measured as described previously (Euhus et al., 1986). All studies were
done according to the guidelines of the University of Texas Southwestern Insti-
tutional Animal Care and Use Committee. Pias1-null mice were generated
with targeted embryonic stem cells obtained from the KOMPT consortium.
A detailed description of their phenotype will be provided in a dedicated
manuscript.
Statistical Analysis
Chi-square test was used for TMA immunohistochemical stain analysis. The
software Prism6 was used for ANOVA tests.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and two tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.05.015.
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